Fig. 1From: HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathwaysCOMP level is increased in the serum of HCC patients. a ELISA analysis of COMP serum level in 100 HCC patients and 30 healthy controls. P = 0.0115 by t test versus normal controls. b ROC curve of serum COMP in 100 HCC patients and 30 normal controls. c and d The overall survival and disease-free survival of HCC patients with high or low level of COMP estimated using the Kaplan-Meier analysis and compared by the Log-rank test in the same set of patientsBack to article page